Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies

about

Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies

Item

http://www.wikidata.org/entity/Q42370340

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cross-talk between cancer-init ...... ions for combination therapies

@en

Cross-talk between cancer-init ...... ions for combination therapies

@nl

type

Item

label

Cross-talk between cancer-init ...... ions for combination therapies

@en

Cross-talk between cancer-init ...... ions for combination therapies

@nl

prefLabel

Cross-talk between cancer-init ...... ions for combination therapies

@en

Cross-talk between cancer-init ...... ions for combination therapies

@nl

P1476

Cross-talk between cancer-init ...... ions for combination therapies

@en

P2093

Amy S Codd

http://www.w3.org/2001/XMLSchema#string

Saly Al-Taei

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Tabi

http://www.w3.org/2001/XMLSchema#string

P2860

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.

Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.

Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches

The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities.

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.

Immunology of cancer stem cells in solid tumours. A review.

Immuno-regulatory antibodies for the treatment of cancer.

P304

S56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2016.10.30

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27868024

http://www.w3.org/2001/XMLSchema#string

P932

5104641

http://www.w3.org/2001/XMLSchema#string